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Abstract
Background: Although low-grade serous ovarian cancer (LGSC) is rare, case-fatality rates are high as most patients
present with advanced disease and current cytotoxic therapies are not overly effective. Recognizing that these cancers may be driven by MAPK pathway activation, MEK inhibitors (MEKi) are being tested in clinical trials. LGSC respond
to MEKi only in a subgroup of patients, so predictive biomarkers and better therapies will be needed.
Methods: We evaluated a number of patient-derived LGSC cell lines, previously classified according to their MEKi
sensitivity. Two cell lines were genomically compared against their matching tumors samples. MEKi-sensitive and
MEKi-resistant lines were compared using whole exome sequencing and reverse phase protein array. Two treatment
combinations targeting MEKi resistance markers were also evaluated using cell proliferation, cell viability, cell signaling, and drug synergism assays.
Results: Low-grade serous ovarian cancer cell lines recapitulated the genomic aberrations from their matching
tumor samples. We identified three potential predictive biomarkers that distinguish MEKi sensitive and resistant lines:
KRAS mutation status, and EGFR and PKC-alpha protein expression. The biomarkers were validated in three newly
developed LGSC cell lines. Sub-lethal combination of MEK and EGFR inhibition showed drug synergy and caused
complete cell death in two of four MEKi-resistant cell lines tested.
Conclusions: KRAS mutations and the protein expression of EGFR and PKC-alpha should be evaluated as predictive
biomarkers in patients with LGSC treated with MEKi. Combination therapy using a MEKi with EGFR inhibition may
represent a promising new therapy for patients with MEKi-resistant LGSC.
Keywords: Ovarian cancer, MEK inhibitor, EGFR inhibitor, PKC-alpha, Predictive biomarkers
Background
Each year in Canada and the United States, over 25,000
women are diagnosed with ovarian cancer [1, 2]. Lowgrade serous ovarian cancer (LGSC) accounts for 5–10%
of these cancers [3, 4], affecting approximately 2000
women per year. This rare form of ovarian cancer is often
diagnosed in pre-menopausal women and frequently
*Correspondence: mark.carey@ubc.ca
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found in advanced stages. Although LGSC is considered
to be a less aggressive subtype than other ovarian cancers, response rates to chemotherapy are low, ranging
from 4 to 25% [5]. Consequently, long-term fatality rates
are high with only 10–20% of women surviving 10 years
after diagnosis [5, 6].
It is now recognized that LGSC has unique clinical,
pathological, and molecular characteristics compared to
other types of ovarian cancers, such as the high-grade
serous ovarian carcinoma (HGSC) [7, 8]. Molecular studies performed on LGSC tumors revealed that mutations
in the TP53 gene are rare (8% in LGSC versus 96% in
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HGSC) [9, 10], and that expression of estrogen (ER) and
progesterone (PR) receptors is frequently observed [11,
12]. LGSC is also characterized by activation of the mitogen-activated protein kinase (MAPK) pathway. Mutations affecting this pathway are seen in KRAS (20–40%),
NRAS (7–26%) and BRAF (5–33%) genes [13–20]. Evidence of MAPK pathway activation in LGSC [21] led to a
key clinical trial evaluating the efficacy of the MEK inhibitor (MEKi) selumetinib for the treatment of patients
with advanced and/or recurrent LGSC (GOG-0239). The
results from this trial, published in 2013, shown a 15%
response rate and 65% disease stabilization [22]. A second clinical trial of the MEKi binimetinib (MILO trial,
NCT01849874) was closed at the interim analysis in
2016, because it did not show the anticipated predefined
benefits on progression-free survival (PFS). Despite these
unexpected results, durable responses to binimetinib
were observed in LGSC with MAPK pathway alterations [23]. Currently, an international randomized phase
II/III clinical trial using the MEKi trametinib is ongoing
(NCT02101788) and a translational research component
to better understand the molecular mechanisms of MEKi
efficacy is included.
To date, preclinical laboratory research in LGSC has
been limited to tumor tissues. The low frequency and
slow growth rate of these tumors have challenged the
development of cell lines and animal xenograft models.
In the past 5 years, our laboratory has successfully established a collection of patient-derived LGSC cell lines
that are now available for pre-clinical drug testing. Previously, we evaluated the effects of four different MEKi
(selumetinib, trametinib, binimetinib, refametinib) in
eight advanced/recurrent LGSC cell lines. Our results
indicated that there were substantial differences in cellular response and on-target drug efficacy between cell
lines and drugs [24]. Encouraged by promising results
from MEKi clinical trials in a subset of LGSC patients, we
sought to identify biomarkers that could predict response
to treatment using LGSC cell lines, by comparing the
proteogenomic profiles of MEKi-sensitive (MEKi-Se) and
MEKi-resistant (MEKi-Re) LGSC cell lines, and subsequently evaluating the potential therapeutic value of two
proteins (EGFR and PKC-alpha) associated with MEKi
resistance.

Materials and methods
Tumor samples and clinical information

Advanced or recurrent LGSC samples (tumor and ascites)
were obtained from the OvCaRe gynecologic tumor bank
(Vancouver General Hospital/British Columbia Cancer
Agency (BCCA), and the John and Mary Knight Translational Ovarian Cancer Research Unit (London Regional
Cancer Program, London, Ontario, Canada). Tumor bank
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protocols, cell line derivation, and all research relating
to this study was approved by institutional human ethics review boards at BCCA (H14-02859), the University
of British Columbia (UBC; R05-0119), and the University
of Western Ontario (HSREB 12668E). Clinical information was extracted retrospectively from patient records.
Tumor histology was confirmed by a gynecological
pathologist.
Patient‑derived LGSC cell lines

Low-grade serous ovarian cancer patient-derived cell
lines were established through continuous in vitro culture of patient material obtained through OvCaRe or
the John and Mary Knight Translational Ovarian Cancer
Research Unit (cell line iOvCa241) tumor banks. Cultures
were established and maintained in M199:MCDB105
(1:1) media (Cat. No. M5017 and M6395, Sigma-Aldrich,
Oakville, Ontario, Canada) supplemented with 10%
defined fetal bovine serum (dFBS; Cat. No. SH30070.03,
Hyclone, GE Life Sciences, Logan, UT, USA) maintained
at 37 °C and 5% C
 O2. No immortalization methods were
used. Doubling time of these cells ranged from 30 to
80 h, with an average of 47 h, reflecting the clinical slow
growth rate of LGSC.
Sample authentication (cell line, tumor, buffy coat)

Microsatellite analysis of short tandem repeats (STRs)
was performed on LGSC cell lines and corresponding
tumor and buffy coat samples for cell line authentication.
STR analyses of 10 loci were performed by Genewiz Inc.
(South Plainfield, NJ) (Data available upon request). STR
results confirm that all LGSC cell lines and buffy coat
samples match to corresponding tumor samples.
Genome sequencing

Whole exome sequencing (WES): Agilent SureSelect RNA
Library All Exons v6 protocol was performed by Beijing
Genome Institute, per manufacturer’s guidelines. Quality and quantity of post-capture libraries were assessed
using an Agilent 2100 Bioanalyzer. Libraries were
sequenced on an Illumina Hiseq 4000 (PE 100). Copy
number variation (CNV) analysis: Data analysis was performed using Nexus Copy Number Discovery Edition
Version 9.0 (BioDiscovery, Inc., El Segundo, CA). Samples were processed using the Nexus NGS functionality
(BAM ngCGH) with the FASST2 segmentation. The log
ratio thresholds for single copy gain and single copy loss
were set at + 0.18 and − 0.18, respectively. The log ratio
thresholds for gain of 2 or more copies and for a homozygous loss were set at + 0.6 and − 1.0, respectively. Tumor
sample BAM files were processed with corresponding normal tissue BAM files. Probes were normalized
to median. Mutation analysis: Sequence alignment and
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mutation calling were performed in Partek Flow environment (© 2017 Partek Inc). Sequence reads were aligned
to GRCh38/hg38 human genome build using bwa 0.7.2.
Variants were called using Strelka 1.0.15 for all cell lines
except for VOA-1312 (lacking buffy coat sample). VOA1312 variant calling was performed using LoFreq 2.1.3.a.
The called variants were annotated using the wAnnovar
software (reference obtained from: http://jmg.bmj.com/
content/49/7/433.citation-tools). Annotated calls were
then filtered to show only protein-changing SNVs that
were present in cell line DNA at allele frequencies (AF)
greater than 0.1 and coverage higher than 16×. For VOA1312, all calls not present in dbSNP (version 138) were
retained, while of the calls that were present in dbSNP,
only calls with (average heterozygocity + aveHet standard
error) < 0.1 were retained. These were additionally filtered
using the same criteria as for the Strelka calls.
Whole genome sequencing (WGS): Genomic data from
LGSC tumors T7 and T11 were obtained from the personalized oncogenomics (POG) program at the BCCA.
Methodology has been previously described in detail
[25]. To summarize, genome and transcriptome libraries were sequenced on HiSeq instruments (Illumina, San
Diego, California) using V3 or V4 chemistry and pairedend 150 or 125 base reads, respectively. Target depth was
80× coverage for the tumor genome and 40× for the normal genome.
Cell proliferation assays

Assessment of MEKi sensitivity using trametinib
(GSK1120212; Sellekchem, Cat. No. S2673) and selumetinib (AZD6244; Cat. No. S1008), were performed as
previously described [24]. Cell proliferation was monitored using IncuCyte™ real-time imaging technology
using a non-labeled monolayer confluence approach
(Essen Biosciences, Ann Arbor, MI, USA). LGSC cell
lines were plated at 15–20% confluence in 96-well plates.
After 24 h, cells were treated once with DMSO (control) or differing drug concentrations [erlotinib alone
(10 μM and 2.5 μM), in combination (10, 5, 2.5, 1.25,
and 0.63 μM), high and low doses of MEKi treatment
(1 μM and 0.5 μM selumetinib; 0.1 μM and 0.05 μM
trametinib; doses for preclinical MEKi assays as previously published)] [24]. Trametinib and selumetinib were
selected as the MEKi for combination treatments. These
two drugs are most commonly used clinically for treating LGSC, and binimetinib may lack efficacy based on
results from the MILO clinical trial (NCT01849874).
Drug doses of selumetinib and trametinib were chosen
based on IC50 results from our previous experiments
[24]. Selected concentrations for these experiments are
in keeping with steady state serum levels (selumetinib
2 μM and trametinib 30 nM) reported for these drugs
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in humans [26, 27]. Phase contrast images of cells were
taken every 6-h for 4–5 days. Each condition was evaluated using four technical replicates and experiments were
repeated for verification. Data analysis was performed
using IncuCyte™ software. Statistical analyses using
the t-test on the final time point values of each assay were
performed to compare treatment conditions. Differences
were considered significant at a p-value < 0.05.
Cell viability assay

Cell viability was measured using MTS-Cell Titer 96R
Aqueous Non-Radioactive Cell Proliferation Assay, following manufacturer recommendations (Cat. No. G5430,
Promega, Madison, WI, USA) at endpoint of Incucyte™
proliferation assays. Treatment media was replaced
with 100 μL of fresh media and 20 μL of MTS. Plates
were incubated for 3.5 h at 37 °C in humidified 5% C
 O2.
Absorbance at 490 nm was measured using a microplate
reader (BioTek Epoch SN257811). Viability for each treatment was compared to DMSO treated cells. Wells were
subsequently stained with crystal violet (CV) to determine residual cells after treatment. Statistical analysis
using t-test were used to compare treatment conditions
and differences were considered significant at a p-value
< 0.05.
IC50 determination

Erlotinib (Cat. No. S7786) were purchased from Selleck Chemicals (Houston, TX, USA). Dimethylsulfoxide (DMSO; Sigma, Cat. No. D2650) was purchased
from Sigma-Aldrich (Oakville, Ontario, Canada). Cells
were seeded in 96-well plates at 40–50% confluence and
treated after 24 h with DMSO or a range of drug concentrations. The inhibitory concentration (IC50, representing 50% of total cell viability) was determined using
crystal violet staining after 72 h drug treatment.
Western blot analysis

Cell lysates were prepared according to previously published protocols [24], then 20 μg samples were separated
on an 8% SDS-PAGE gel, transferred to nitrocellulose
membranes and probed with primary antibodies including ERK1/2 (Millipore, Cat. No. 06-182), p-MAPK
(p-ERK1/2, Cell Signaling, Cat. No. 4376S), MEK1/2
(Cell Signaling, Cat. No. 9122), p-MEK1/2 (Cell Signaling, Cat. No. 9154), PKC-alpha (Cell Signaling, Cat. No.
2056), EGFR (Santa Cruz, Cat. No. 71032), p-EGFR (Cell
Signaling, Cat. No. 2234), PARP (Cell Signaling, Cat.
No. 9542), and c-PARP (Cell Signaling, Cat. No. 9541S).
Vinculin (V9131, Sigma) was used as a protein loading
control. Horseradish peroxidase (HRP)-conjugated secondary antibodies (goat-anti-mouse or goat-anti-rabbit,
Sigma Cat. No. A9917 and A0545) were used accordingly.
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Western blots were imaged using Immobilon HRP reagent (Cat. No. WBKLS0500, Millipore, Etobicoke, ON,
Canada) and developed by autoradiograph.
Reverse‑phase protein array (RPPA) analysis

Reverse-phase protein array on whole tumor and cell line
lysates was performed as previously described [28, 29].
Proteomic profiles of 8 LGSC cell lines, 2 MEKi-sensitive
(VOA-1312, iOvCa241) and 6 MEKi-resistant (VOA1056, VOA-3993; VOA-3448, VOA-3723; VOA-4627,
VOA-4698), were analyzed. LGSC cells were treated for
24 h with 1 μL/mL DMSO or MEKi (trametinib 0.1 μM,
selumetinib 1.0 μM) in biological triplicate as previously
described [24, 30]. Antibodies (n = 91) against cell surface growth factor receptors, common signaling pathway
proteins, steroid hormone receptors, and other proteins
involved in proliferation and apoptosis were used (Additional file 1: Table S1). Data was analyzed using SPSS
software (Version 20, Chicago, Illinois). Differentially
expressed proteins between cell lines and treatment conditions were determined using the t-test [31]. The Mann–
Whitney U test was used for proteins with non-normally
distributed expression levels. False discovery rates were
not calculated as putative markers were validated by
western blot.
shRNA‑mediated knockdown of PKC‑alpha expression
(PRKCA gene)

shERWOOD-UltramiR shRNA lentiviral target gene
set containing three PRKCA shRNA sequences and one
non-target shRNA (Cat. No. TLHVU1401-5578) was
purchased from transOMIC Technologies (Huntsville,
AL). VOA-3723 and VOA-6406 were plated at 50% confluence in 6-well tissue culture dishes 24 h prior to lentiviral transduction. 199:105 media supplemented with
1% Hyclone dFBS and polybrene (2 µg/mL for VOA3723, 0.5 µg/mL for VOA-6406) and lentivirus expressing non-targeting shRNA or PRKCA shRNA (multiplicity
of infection [MOI] = 26 for VOA-3723, MOI = 1.5 for
VOA-6406) in a total volume of 1.5 mL was added. After
24 h, cells were washed with PBS and complete media
was added. Successful transduction was confirmed using
confocal microscopy. After an additional 24-h recovery,
transduced LGSC cells were selected and maintained
using puromycin (1.0 µg/mL for VOA3723, 0.5 µg/mL for
VOA6406).
Drug synergy analysis

Cell proliferation, viability and crystal violet results
from in vitro drug testing (single drug and drug combinations) were used to assess drug synergism using
CompuSyn software (http://www.combosyn.com). This
software is based on the median-effect principle and the
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combination index-isobologram theorem (Chou-Talalay)
[32]. Drug doses (D) and effects (fa) were entered (nonconstant ratios) for single drug doses and combinations,
and combination indices (CI) were generated. The CI
values quantitatively defined synergism (CI < 1), additive
effect (CI = 1), and antagonism (CI > 1).

Results
Development and MEKi treatment evaluation of LGSC cell
lines

Our laboratory previously established a collection of
LGSC cell lines derived from patients with advanced/
recurrent disease. Preclinical evaluation of four MEKi in
eight different LGSC cell lines resulted in the identification of two distinct phenotypes: MEKi-sensitive (MEKiSe) cell lines (n = 2), and MEKi-resistant (MEKi-Re) cell
lines (n = 6). In this first study, MEKi drug concentrations
and IC50 values were reported [24]. Recognizing the
challenges using IC-50 values to assess drug efficacy invitro, we established a stringent definition of MEKi sensitivity/resistance recognizing that only 15% of patients
with advanced/recurrent LGSC will show tumor experience regression when treated with a MEKi. Thus, we
classified cell lines as MEKi-Se if a single dose of MEKi
resulted in complete cell death over a period of 5 days.
Alternatively, cell lines were considered MEKi-Re if they
continued to proliferate (even despite some degree of
inhibition) under the same treatment conditions. Continuing our previous work, we established three new LGSC
cell lines from three independent patients (VOA-6406,
VOA-8862, VOA-9164). Tumor cells from three other
LGSC patients were also grown temporarily as primary
cultures (VOA-6800, VOA-6857, VOA-7604). Using our
previous classification criteria, two of these new lines
were classified as MEKi-Se (VOA-9164 and VOA-8862),
and one as MEKi-Re (VOA-6406—see Additional file 2:
Figure S1). STR analysis confirmed unique microsatellite
profiles for each of these lines, matching the profiles of
the original tumor tissues from which they were derived
(data available upon request).
Genomic characterization of MEKi‑Se and MEKi‑Re LGSC
cells

WES was performed to characterize the genomic profiles of our LGSC cell lines and primary cultures. First,
we compared the copy number profiles of two of our
cell cultures (VOA-4627, VOA-6857) with those of their
associated tumor samples (from WGS data). As shown
in Fig. 1, the copy number variation profiles of the paired
samples showed a very high degree of correlation. Of
note, VOA-4627 line was derived from an ascites sample
taken 2 years after the tumor sample collected previously
at cytoreductive surgery.
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(See figure on next page.)
Fig. 1 Comparison of genomic profiles between two LGSC cell cultures and their associated LGSC tumor samples. Each graph represents the
copy-number (CN) changes detected per chromosome in each sample. Top graphs correspond to LGSC patient #6; CN changes detected in one
of her recurrent tumor tissues was compared to the CN changes detected in the primary cell culture derived from this tissue. Bottom graphs
correspond to the LGSC patient #9; CN changes detected in one of her recurrent tumor tissues was compared to the CN changes detected in the
cell line established from a later recurrent tissue. High genomic profile correlation was observed between cells and tumors in both cases

Results from the WES analysis in our LGSC cell lines
and primary cultures (n = 14) show variable levels of
genomic aberration and non-synonymous mutations
(NsMs), ranging from 1 to 66% total genome change
and 24-111 mutation calls per cell line (Additional file 3:
Table S2a). Deletion of Chr9p, including loss of MTAP
and CDKN2A tumor suppressor genes, was found in all
samples. As expected, KRAS and NRAS non-synonymous
mutations were both found most frequently. Either mutation was present in 28.6% of all cell lines/cultures, and
in 36.4% (KRAS) and 27.3% (NRAS) respectively when
analyzed by patient (some cell lines were derived from
the same patient at different times). KRAS and NRAS
mutations co-existed in only one cell line (VOA-8862).
Only one BRAF mutation was detected (D594G variant; VOA-6800 culture). Additionally we analyzed gene
mutations and copy-number changes affecting 61 wellknown MAPK-pathway genes is shown in Additional
file 3: Table S2b. A summary of all RAS mutations, copynumber variation (CNV) findings, and MEKi sensitivity
in each LGSC cell culture (n = 14) is shown in Table 1.
We found that all MEKi-Se cell lines (4/4; iOvCa241,
VOA-1312, VOA-9164, VOA-8862) carried oncogenic
mutations in KRAS (G12D or G12V), while MEKi-Re
cell lines were either NRAS mutant (3/7; VOA-1056/
VOA-3993 and VOA-6406), or KRAS/NRAS wt (4/7;
VOA-3448/VOA-3723 and VOA-4627/VOA-4698). Of
interest, the VOA-8862 cell line (mutations in both KRAS
and NRAS) was found to be sensitive to all four MEKi
tested. In this line, the KRAS mutation variant detected
(G12D) is known to be oncogenic, while the NRAS mutation variant detected (C118Y) was not found in the COSMIC database, therefore its oncogenic potential remains
unknown. We did not observe any obvious correlation
between the degree of CNV in each cell line (copy number high versus low) and MEKi response.
Proteomic differences between MEKi‑Se and MEKi‑Re LGSC
cell lines

To identify biomarkers of MEKi response, we compared
two MEKi-Se (VOA-1312, iOvCa241) and six MEKiRe (VOA-1056/VOA-3993, VOA-3448/3723, VOA4627/VOA-4698) LGSC cell lines using reverse phase
protein array (RPPA) analysis. To do so, lines treated
with DMSO, 1 μM selumetinib, or 0.1 μM trametinib
were screened using a panel of 91 validated antibodies

(see “Materials and methods” and Additional file 1:
Table S1). We found 12 proteins that were differentially
expressed between MEKi-Se and MEKi-Re cell lines
(Additional file 4: Table S3). Among these proteins,
EGFR and PKC-alpha were found to be overexpressed
in all MEKi-Re lines independently of the treatment
status. These two candidates were selected for validation and further study as they are regulators of MAPK
signaling and play a role in MEKi and chemotherapy
resistance in the literature [33–37]. WB analysis confirmed these findings (Fig. 2a), and also showed that
p-EGFR (Y1068) was overexpressed in the MEKi-Re
lines. Subsequently we subsequently validated the same
candidates in the three newly established LGSC cell
lines (VOA-6406, VOA-8862, VOA-9164) (see Fig. 2b).
In keeping with the discovery cohort results, the MEKiRe line (VOA-6406) expressed much higher levels of
EGFR, p-EGFR and PKC-alpha than the two MEKi-Se
lines (VOA-9164, VOA-8862) (Fig. 2b). As we previously described, p-MEK and p-ERK1/2 expression were
not found to distinguish sensitive and resistant lines by
WB [24].
We subsequently assessed differential protein expression by RPPA between MEKi-Se and MEKi-Re cell lines
after selumetinib and trametinib treatment. Twentyone and seventeen proteins were significantly different
between MEKi-Se and MEKi-Re cells after selumetinib
and trametinib treatment, respectively (Additional file 4:
Table S3). Confirmation of the RPPA results was assessed
by WB in one representative cell line from each individual patient (VOA-3993, VOA-4627, VOA-3723). Cell
lines derived from the same patients at different time
points in the disease course were not included for this
analysis (VOA-1056, VOA-4698, VOA-3448). As seen
in the untreated cells, WB confirmed increased p-EGFR
levels in the MEKi-Re cell lines (Fig. 2c, d). As expected,
trametinib more effectively inhibited MAPK phosphorylation than selumetinib. Differences in GSK3B and BID
protein expression were also observed between MEKi-Se
versus MEKi-Re cells by RPPA, however we were unable
to validate these results using mass spectrometry (MS)
analysis (data not shown). Interestingly, a number of the
differentially expressed proteins (MEK-Se versus MEKRe) were found to be drug-specific. These RPPA screening results are summarized in Additional file 4: Table S3,
though these findings require further validation.
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imbalance,
CN gain;
NRAS: CN loss;
BRAF: alellic
imbalance,
CN gain

KRAS: allelic
0.50
imbalance, CN
gain

KRAS (G12V)a

0.30

Resistant

Resistant

Resistant

Resistant

Sensitive

Sensitive

Sensitive

Sensitive

Selumetinib Trametinib MEKi drug
IC50 (μM)
IC50 (μM) response

KRAS: allelic
imbalance,
CN gain

CNV changes
affecting
KRAS/NRAS/
BRAF genes

KRAS (G12D)

KRAS/
NRAS/BRAF
mutation
status
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VOA-6857

VOA-7604

VOA-6800

9

10

11

Cell line

Treatment naïve

Transient
culture

Transient culture

Post chemoTransient
therapy,
culture
anti-hormone
therapy, and
MEKi therapy

Post chemotherapy

Advanced LGSC Post chemotherapy

Advanced LGSC
with SBT

Recurrent LGSC

Advanced LGSC

Post chemoCell line
therapy,
anti-hormone
therapy, and
targeted
therapy

29

25

27

23

50

56

% genome
change
by WES

68

61

83

80

110

111

Total number
nonsynonymous
AA changes

BRAF (D594G)

Wild type

Wild type

NRAS (Q61R)

Wild type

Wild type

KRAS/
NRAS/BRAF
mutation
status

n/a

0.64

11.67

8.75

None

n/a

n/a

n/a

n/a

≤ 0.05

0.08

0.08

n/a

n/a

n/a

Resistant

Resistant

Resistant

Selumetinib Trametinib MEKi drug
IC50 (μM)
IC50 (μM) response

KRAS: allelic
n/a
imbalance, CN
gain

None

NRAS: CN gain

KRAS: CN gain;
NRAS: CN
gain; BRAF:
LOH

KRAS: CN gain;
BRAF: LOH

CNV changes
affecting
KRAS/NRAS/
BRAF genes

a

No buffy coat available; somatic from germline mutations are undiscernable

LGSC low grade serous ovarian carcinoma, MP micropapillary, MPSBTmicropapillary serous bordeline ovarian tumor, SBT serous borderline ovarian tumor, WES whole-exome sequencing analysis, CNV gene copy number
variation, AA aminoacids, IC50 50% cell inhibitory concentration

The same typeface (roman or italic) has been used to help group cell lines from the same patient

VOA-6406

8

Recurrent LGSC

VOA-4698

Post chemoCell line
therapy,
anti-hormone
therapy, and
targeted
therapy

Recurrent LGSC

VOA-4627

7

Cell culture
type

Treatment
status
at collection

Patient Sample name Pathology
number
at collection

Table 1 (continued)
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+ Selumetinib

c
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VOA -3723

VOA-3448
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Untreated*

VOA -6406
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p-MAPK
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MAPK
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Fig. 2 Differential expression of EGFR, p-EGFR and PKC-α between MEKi-Se and MEKi-Re LGSC cell lines by WB. a Confirmation of the RPPA results
in untreated MEKi-Se and MEKi-Re lines (a, discovery cohort). EGFR, p-EGFR and PKC-α were increased in MEKi-Re lines (n = 5) compared to MEKi-Se
lines (n = 2). b Validation of these protein biomarkers in three newly established LGSC cell lines classified according to their MEKi responsiveness
(validation cohort). As found in the cell lines analyzed by RPPA, the new MEKi-Re line (n = 1) expressed higher levels of EGFR, p-EGFR and PKC-α
compared to the two new MEKi-Se lines tested (n = 2). c, d Confirmation of RPPA results in MEKi treated cell lines. With MEKi treatment (selumetinib
1 μM and trametinib 0.1 μM) p-EGFR expression remained higher in MEKi-Re lines. As previously described, trametinib showed stronger inhibitory
effects on MAPK (p-MAPK or p-ERK1/2) than selumetinib, even when used at ten times lower dose. (*) No DMSO. (**) Untreated VOA-4627 cells to
control for drug inhibition effects on MAPK pathway

In vitro evaluation of MEK and EGFR inhibition in MEKi‑Re
LGSC cell lines

To establish whether EGFR expression played a role
in mediating MEKi resistance we evaluated the effects
of EGFR inhibition (using erlotinib), with and without
MEK inhibition (using selumetinib or trametinib), in four
MEKi-Re LGSC cell lines (VOA-3723, VOA-3993, VOA4627, and VOA-6406). IC50 values for erlotinib in these
cell lines are shown in Additional file 5: Table S4. Except
for VOA-3723, all MEKi-Re lines were highly resistant
to single erlotinib treatment as observed in other ovarian cancer cell lines [38, 39]. Erlotinib doses chosen for

the combined experiments are in keeping with erlotinib
human serum levels [40]. Effects of single and combined
drug treatment were evaluated using proliferation, viability, and WB assays. EGFR mutation and copy-number
status were also evaluated. By WES, none of our LGSC
cell lines carried activating mutations in EGFR, though
some had copy-number changes affecting this gene. As
summarized in Additional file 5: Table S4, we could not
identify any obvious factors [EGFR CNV levels, levels of
EGFR protein expression, phosphorylation, or sensitivity
(IC50 values) to erlotinib treatment] that were associated
with sensitivity to combination therapy.
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(*) Statistically significant, p<0.05
(§) Non-significant

Fig. 3 Effects of selumetinib and erlotinib single and combined drug treatments in four MEKi-Re LGSC cell lines. The graphed curves (a) represent
the results from the proliferation experiments and the bar graphs (b) represent the results from the viability (MTS and CV) assays performed at
the end of the proliferation experiments. The photomicrographs (c) show IncuCyte™ images at the completion of the experiment. All four cell
lines were resistant to single selumetinib and erlotinib treatments. However, when the drugs were combined, VOA-6406 and VOA-3723 cell lines
demonstrated complete cell death while VOA-4627 and VOA-3993 cells were shown to be resistant to the dual selumetinib and erlotinib treatment
combination

With the highest dose of erlotinib treatment alone
(2.5 μM, one dose, over 4–5 days), all four MEKi-Re cell
lines continue to proliferate. Interestingly as shown in
Fig. 3, a reduced dose of selumetinib (0.5 μM) in combination with erlotinib (2.5 μM) resulted in statistically
significant decreases in cell proliferation and viability
(p < 0.001; t-test) in 2 of the 4 cell lines tested (VOA-3723
and VOA-6406). At the end of these experiments, complete cell death of both cell lines was confirmed by image
inspection on Incucyte™ (Fig. 3; and Additional file 6:
Figure S2). Using Compusyn software analysis, synergistic drug effects (were demonstrable even using lower
doses of erlotinib (1.25 or 0.63 μM) with selumetinib

(0.5 μM) (Additional file 7: Table S5). These drug combinations were not effective in the other two lines tested
(VOA-3993 and VOA-4627). Reduced dose of trametinib
(0.05 μM) in combination with erlotinib (2.5 μM) resulted
in similar results for the VOA-3723 cell line, but cytostatic effects for the VOA-6406 cell line. A summary of
the synergistic drug effects are shown in Additional file 7:
Table S5. Drug synergy was stronger with selumetinib
and erlotinib combination than with trametinib and erlotinib combination.
The effects of erlotinib, with and without MEKi treatment, on EGFR and MAPK signaling pathways were
evaluated using WB. Levels of total and phosphorylated
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therapy (MEKi and erlotinib), the trametinib and erlotinib combination resulted in more apoptosis induction
than the selumetinib and erlotinib combination (as measured by c-PARP).
Effects of PKC‑alpha inhibition in MEKi‑Re LGSC cell lines

Erlotinib 2.5μM + Selumetinib 1.0μM

Selumetinib 1.0μM

Erlotinib 2.5μM + Selumetinib 0.5μM

Selumetinib 0.5μM

Erlotinib 2.5μM

VOA-3993

DMSO

Selumetinib 1.0μM

Selumetinib 0.5μM

DMSO

VOA-4627

Erlotinib 2.5μM + Selumetinib 1.0μM

Genomic characterization of PRKCA by WES revealed
that none of our LGSC cell lines carried activating mutations in PRKCA. It is interesting to note that two MEKiRe cell cultures (VOA-3723 and VOA-6857) carried
PRKCA copy-number gain and two MEKi-Se cells (VOA9164 and VOA-8862) had PRKCA copy-number loss. To
determine whether PKC-alpha protein expression played
a role in mediating MEKi resistance we evaluated the
effects of PKC-alpha knockdown using lentiviral shRNA,
with and without selumetinib or trametinib in two
MEKi-Re LGSC cell lines (VOA-6406 and VOA-3723).
As shown in Fig. 5a, PRKCA shRNA resulted in a complete PKC-alpha protein knockdown in VOA-6406 cells
and a partial knockdown in VOA-3723 cells by WB. Subsequent MEKi treatment (1.0 μM selumetinib or 0.1 μM
trametinib) experiments showed no significant changes

Erlotinib 2.5μM + Selumetinib 0.5μM

Erlotinib 2.5μM + Selumetinib 1.0μM

Selumetinib 1.0μM

Selumetinib 0.5μM

Erlotinib 2.5μM
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Selumetinib 1.0μM
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Erlotinib 2.5μM

DMSO

VOA-6406

Erlotinib 2.5μM + Selumetinib 0.5μM

EGFR and ERK1/2, as well as total and cleaved PARP
(c-PARP) were measured after 24 h treatment. Results
from these experiments indicated that drug effects on
cell signaling were cell line dependent (Fig. 4; and Additional file 8: Figure S3). As previously reported by our
group, trametinib alone (0.1 μM) caused stronger inhibitory effects on ERK1/2 phosphorylation (p-ERK1/2) than
selumetinib (1 μM). Unexpectedly, selumetinib treatment
increased EGFR phosphorylation (p-EGFR Y1068) in 3
out of 4 MEKi-Re cell lines (VOA-6406, VOA-3723, and
VOA-4627), however these effects were less obvious with
trametinib treatment. As expected, erlotinib alone inhibited EGFR phosphorylation (p-EGFR Y1068) in all cell
lines. Interestingly, erlotinib alone also inhibited ERK1/2
phosphorylation in 2 out of 4 lines (VOA-3723 and VOA4627) and activated ERK1/2 phosphorylation in another
line (VOA-6406). No pathway interaction was detected
in the resistant VOA-3993 cell line. In these lines, while
pathway interaction was observed, none of the changes
in p-EGFR Y1068, p-ERK1/2 or c-PARP correlated with
sensitivity or resistance to dual EGFRi and MEKi treatment. In the two MEKi-Re lines resistant to combination

Erlotinib 2.5μM
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Fig. 4 Cell signaling effects of selumetinib and erlotinib treatments in four MEKi-Re LGSC cell lines. As previously described, 24 h selumetinib
treatment caused an increased in the levels of EGFR phosphorylation (p-EGFR Y1068) in 3 out of 4 MEKi-Re cell lines (VOA-6406, VOA-3723, and
VOA-4627). As expected, erlotinib alone inhibited EGFR phosphorylation (p-EGFR Y1068) in all cell lines. Interestingly, erlotinib also inhibited
MAPK phosphorylation (p-ERK1/2) in 2 out of 4 lines (VOA-3723 and VOA-4627), and increased it in another line (VOA-6406). No unique pathway
interaction patterns for each of the MEKi-Re lines that were sensitive (VOA-6406, VOA-3723) or resistant (VOA-4627, VOA-3993) to erlotinib and
selumetinib combination was detected

(See figure on next page.)
Fig. 5 Effects of PRKCA knockdown in two MEKi-Re LGSC cell lines using lentiviral shRNA. a Determination of PKC-alpha (PKC-α) protein expression
by WB. Transduction with lentiviral particles containing PRKCA shRNA resulted in a complete PKC-α protein knockdown in VOA-6406 cells and a
partial knockdown in VOA-3723 cells. As detected by WES, VOA-3723 cells display PRCKA CN gain, which may explain the partial PKC-α protein
knockdown. b Effects of PRKCA knockdown on cell proliferation. Reduction of PKC-α levels alone did not compromise cell proliferation in either
of the two cell lines tested. Furthermore, PRKCA knockdown in combination with selumetinib treatment did not seem to significantly increase the
sensitivity of these lines to selumetinib treatment. c Effects of PRKCA knockdown on cell viability (MTS and CV assays). As seen in these bar graphs,
and similar to what we observed in the proliferation experiments, PRKCA knockdown did not seem to impact the viability of these lines
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in cell viability when compared to non-target shRNA
transduced lines (Fig. 5b). Proliferation assays demonstrated that PKC-alpha knockdown did not increase
MEKi sensitivity in the VOA-3723 cells, but may slightly
increase MEKi sensitivity to selumetinib in the VOA6406 cell line (p = 0.048). This treatment combination
was much less effective than EGFRi and MEKi combination in MEKi-Re LGSC cell lines as the cells continue to
proliferate. Taken together, these results do not support
PKC-alpha as a treatment target in LGSC to expand the
efficacy of MEKi treatment.

Discussion
Activating mutations affecting the MAPK pathway (RAS/
RAF/MEK/ERK) are frequently found in cancer. MAPK
pathway inhibitors, such as MEK inhibitors, were developed as targeted therapeutics to potentially treat such
cancers [41, 42]. MEKi as single agents or in combination with other therapies have been studied for the treatment of melanoma, lung and colorectal cancers [43]. In
2013, the MEKi selumetinib was evaluated in a phase II
clinical trial as a treatment for LGSC. Clinical responses
(RECIST-1.1) to MEKi were observed in 15% of patients
[22, 44]. While these responses were limited, response
rates using conventional chemotherapy in patients with
relapsed LGSC are disappointingly low (4%) [45]. More
recently, a number of LGSC cases have been reported,
highlighting dramatic and durable responses to MEKi
treatment [22, 23, 46, 47]. Currently, there are no predictive biomarkers of MEKi response for LGSC. Identifying
molecular markers which predict MEKi treatment efficacy will allow for pre-selection of patients who would
benefit from this treatment, and avoid ineffective treatments and toxicities in those patients unlikely to respond.
In this study, we utilized genomic and proteomic techniques to molecularly characterize a collection of LGSC
cell lines and primary cultures (derived from advanced/
recurrent LGSC patients), and identify markers that predict response (sensitivity/resistance) to MEKi treatment
in vitro. Genomic profiles of two of these cell models
were compared with their corresponding tumor samples
from the same patient and showed remarkably similar
copy number profiles, supporting the utility of these cell
models for preclinical research. Subsequent comparisons
of genomic profiles from an additional twelve LGSC cell
models showed frequent deletion of Chr9p (including
loss of MTAP and CDKN2A genes) [48, 49] and oncogenic mutations in KRAS and NRAS genes, in agreement
with results from previous studies on LGSC tumor tissues [13–15]. Additionally, RAS mutations were often
associated with RAS copy number gain. As previously
reported [24, 46, 50] we also detected multiple and distinct genomic alterations affecting other genes related to
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the MAPK cell signaling pathway. It is worth noting that
the individual comparison of genomic profiles between
LGSC cultures showed substantial variations in the types
of gene mutations and copy-number alterations, indicating widespread molecular differences in LGSC tumors
between patients.
Further evaluation of mutation profiles in eight LGSC
cell lines with different sensitivity to MEKi treatment
(two MEKi-Se and six MEKi-Re) showed oncogenic
mutations in KRAS in all four MEKi-Se lines which were
absent in all six MEK-Re lines. Previous results from a
clinical trial using selumetinib (Farley et al. [22]) did not
find a significant relationship between RAS mutation
status and MEKi response rates in LGSC patients. It is
important to note that tumor samples were not available
for testing in 35% of the patients (18 of 52) in this study.
In agreement with our results, two recent case reports
on LGSC patients with remarkable and durable clinical responses (> 5 years) to MEKi therapy have reported
oncogenic KRAS mutations (both G12V) in their tumors
[23, 47]. As LGSC is often an indolent disease, the inclusion of patients with stable disease should also be considered in the future evaluation of RAS mutation status as
a predictive biomarker. It is not unexpected that a single
biomarker, such as KRAS mutation status, will not accurately predict responses to MEKi treatment, recognizing
that LGSC harbor other MAPK-pathway gene mutations
and significant MAPK copy number changes. Furthermore, KRAS copy-number amplification (described as
one activating mechanism) could also play a role in mediating MEKi efficacy [44].
Using RPPA to compare MEKi-Se and MEKi-Re LGSC
cell lines, we found that all MEKi-Re lines had higher
levels of EGFR and PKC-alpha expression. These results
were subsequently validated in three newly established
LGSC cell lines. Using this approach, we also described
proteomic changes specific to each MEKi tested (selumetinib or trametinib). The changes we observed may
be particularly relevant when evaluating differences in
drug efficacy, as MEKi may exhibit differences in MEK
isoform specificity or off-target effects [24]. Interestingly,
all MEKi-Re lines expressed higher levels of EGFR activation (p-EGFR Y1068) than the MEKi-Se lines. Although
our study was limited to a small number of cell lines, we
did not observe an obvious correlation between levels of
EGFR and PKC-α protein expression and specific gene
mutations or copy number changes in these genes.
In colorectal cancer, preclinical studies with BRAF
inhibitors have reported adaptive feedback reactivation
of MAPK signaling involving EGFR [33, 51]. This feedback signaling can be blocked by the addition of a MEKi.
We similarly found evidence of MAPK feedback signaling following MEKi treatment that appears to play a role
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in MEKi resistances. Half of the MEKi-Re cells (2/4 cell
lines) were effectively treated with selumetinib in combination with erlotinib, causing complete cell death. Combination therapy was effective in these two cell lines using
drug doses that were below those that lacked efficacy as
single drug treatments. Drug synergy was demonstrated
using CompuSyn analyses in the two cell lines where cell
death was demonstrated. In contrast, the other two lines
tested continued to proliferate even with higher doses of
the drug combination. We were unable to observe any
obvious changes in p-EGFR and/or p-ERK that characterized the two combination-therapy resistant cell lines. As
seen in our previous study [24], trametinib appeared to
be a more effective inhibitor of ERK phosphorylation and
cell proliferation than selumetinib. Based on its enhanced
efficacy, it was more difficult to detect drug synergism
using the erlotinib/trametinib combination than with the
erlotinib/selumetinib combination.
There is a growing body of evidence supporting the
use of combining a targeted therapy with other targeted
agents or with traditional chemotherapeutic agents [29,
52]. Combination therapy using erlotinib and selumetinib
was studied in a randomized phase II trial in lung cancer [53]. This drug combination did not prove to be
effective in lung cancers irrespective of KRAS mutant
status. Though the treatment was tolerated, significant
side effects occurred with combination therapy. If these
drug treatment combinations are going to be effective in
LGSC, optimal drug dosing will be required in order to
minimize side effects without loss of treatment efficacy.
Combination therapy with BRAFi and MEKi has
remarkably improved survival in the adjuvant setting for
patients with BRAF mutant melanomas, and combining
a BRAFi and an EGFRi has improved tumor regression
in BRAF mutant colorectal cancer xenografts [51, 54]. In
a recent report, binimetinib in combination with paclitaxel was studied in platinum resistant ovarian cancer
patients (NCT01649336). Two LGSC patients included
in this trial showed response to this drug combination. These cases had also the largest reduction in target
lesion size among the 25 ovarian cancer patients studied.
MAPK pathway aberrations (KRAS G12D mutation and a
CUL1:BRAF fusion) were identified in the tumors of both
patients [44]. Additionally, two more LGSC patients with
KRAS G12V [23, 47] and one with MEK1 (Q56_V60del)
gene mutations experienced disease stabilization in
response to this drug treatment combination [46].
PKC-alpha expression has been implicated in chemotherapy drug resistance in some cancers [36, 37]. To
explore its potential role in MEKi resistance, we inhibited PKC-α expression in two MEKi-Re lines. In the cell
line where complete PKC-alpha protein knockdown
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was achieved, the effect of this treatment combination
was not nearly as effective as combining MEKi and
EGFRi. In the other line, where only partial knockdown
of PKC-alpha protein expression was obtained, no
changes in MEKi sensitivity were observed. Of interest,
we found that this line contained PRKCA copy number gain. PKC-alpha knockdown by itself did not affect
cell proliferation in either cell line. The results of our
experiments suggest that PKC-alpha protein expression
appears to be a predictive biomarker but is not a therapeutic target mediating MEKi resistance.
Identifying molecular characteristics to predict
drug sensitivity/resistance in individual patients with
solid tumors has proved to be challenging. The efficacy of therapies designed to target specific mutations are known to be dependent on the cancer type.
For example, while BRAF inhibitors have shown to
be effective in melanomas carrying BRAF mutations,
they have demonstrated little effect in the treatment of
BRAF mutant colon cancers [33, 55, 56]. In advanced
LGSC, mutations in KRAS are more common than in
BRAF [14, 19, 57, 58]. While MEKi have shown efficacy in some LGSC, still only a minority of patients
respond to this treatment. Thus, it is of utmost importance to identify markers of drug treatment efficacy
specific for each cancer type. A current clinical trial
using the MEKi trametinib to treat patients with LGSC
(NCT02101788), will include a translational research
component in an attempt to identify predictive biomarkers in patient tumor samples.

Conclusions
In summary, this proteogenomic study is the first to
perform predictive biomarker discovery for MEKi
treatment in LGSC cell lines. MEKi-Se cell lines were
found to have oncogenic KRAS mutations and low levels of EGFR and PKC-alpha protein expression. The
confirmation of these results in MEKi treated LGSC
tumors samples could lead to better patient selection
for MEKi treatment, and further avoid unnecessary
treatment and toxicities in patients unlikely to respond.
Our study also suggests that a significant portion of
those LGSC patients whose tumors are unresponsive to
MEKi therapy may benefit from combination therapy
with EGFR and MEK inhibition. As LGSC xenografts
are not yet available for research, we are currently unable to validate these results in vivo. However, we are
now using our LGSC patient-derived cell lines to establish xenograft models. The potential predictive value of
the three molecular markers of MEKi response identified in our LGSC cell line models should be considered
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for further validation in clinical trials using MEKi for
the treatment of LGSC.
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